Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in Acute Decompensated Heart Failure
NCT05346653Phase 4Terminated
- Sponsor
- University of Chicago
- Start
- May 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in heart failure (HF), sponsored by University of Chicago. Started May 2023; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05346653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346653.